Artificial Intelligence and Neuro-Medicine: Emerging Trends in Bipolar Disorder, Glioblastoma and Alzheimer’s Disease

Authors: Pandey S*

DOI: 10.23880/nnoaj-16000178

Volume 8, Issue 2

Abstract

Dissecting the intricate “neuro-immune cross-talks” in the complex etiopathogenesis of neurological disorders primarily bipolar disorder, glioblastoma and Alzheimer’s disease in genetically disparate susceptible cohorts of heterogeneous population-pools by amalgamating precision-based therapeutic targeting of Ceramide-Wnt/ Frizzled-Toll like receptors-autophagy biochemical/ metabolic signaling cascades with Artificial Intelligence (AI) offers fascinating healthcare management avenues in eventual pragmatic, evidence-based predictive biomarker development in the Covid-vaccination era [1-4]. Moreover, CRISPR-Cas genetic engineering technology has emerged as an enigmatic modulator of complex human genetic diseases including neurological diseases utilizing genome editing and detecting specific DNA/RNA sequences to gene expression control warranting future dynamic collaborations for immuno-inflammatory disease(s)-management in neuromedicine in the global Covid-19/Omicron pandemic and Covid-19 vaccination era [5]. In my expert opinion, the disproportionate share of psychosocial distress and neurobehavioral deficits warrants a robust, evidence-based, pragmatic “AI-bioengineering immunotherapeutic model” for design of pharmacological scaffolds, novel drugs and clinically validated predictive biomarkers for effective management of bipolar disorder, Alzheimer’s disease and glioblastoma amongst genetically susceptible at-risk cohorts

Keywords: Etiopathogenesis; Neurological Disorders; Alzheimer’s Disease; Neurons

View PDF